<SEC-DOCUMENT>0000939767-26-000096.txt : 20260805
<SEC-HEADER>0000939767-26-000096.hdr.sgml : 20260805
<ACCEPTANCE-DATETIME>20260805160937
ACCESSION NUMBER:		0000939767-26-000096
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260805
DATE AS OF CHANGE:		20260805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		261243544

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20260805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019dff77-f9ff-73e7-920a-460f0f3405e9,g:f654a1f8-8503-4e93-9618-208823627eeb,d:1ffb7ae7e3c64e78a9f898f4d99cc957-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20260805</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20260805.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1ffb7ae7e3c64e78a9f898f4d99cc957_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 05, 2026</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img src="exel-20260805_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px" id="i-1"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Commission File Number)</span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:1.5pt 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:1.5pt 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1ffb7ae7e3c64e78a9f898f4d99cc957_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;5, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended July&#160;3, 2026, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exel20260630exhibit991.htm">Press Release issued August 5, 2026</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1ffb7ae7e3c64e78a9f898f4d99cc957_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 5, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Brenda J. Hefti</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brenda J. Hefti</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and General Counsel <br/></span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>exel-20260805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019dff77-f9ff-73e7-920a-460f0f3405e9,g:f654a1f8-8503-4e93-9618-208823627eeb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20260805" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20260805">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20260805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20260805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>exel-20260805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019dff77-f9ff-73e7-920a-460f0f3405e9,g:f654a1f8-8503-4e93-9618-208823627eeb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019dff77-fa00-7c34-8c4d-f0acb4565963_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019dff77-fa00-7bf2-bf3e-53d0339ebd84_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019dff77-fa00-7a78-97c8-50ecebb0e3c2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019dff77-fa00-7bda-b781-a875a3be004d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019dff77-fa00-7bc3-8f50-01c8d731d881_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019dff77-fa00-77d3-8c80-70f786c4481b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019dff77-fa00-754a-adaa-c7e668c83e78_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019dff77-fa00-762b-9cdd-555145acef5c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019dff77-fa00-7845-afb2-dd98e5300d14_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019dff77-f9ff-7a1b-9e2b-f3f5b282aef9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019dff77-fa00-7df7-b2e4-016c065a0781_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019dff77-fa00-77f5-9a16-1d8c7a5d17bb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019dff77-fa00-7420-a9fd-7b30bbc7b052_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019dff77-fa00-7c84-aca2-fd6d5787aa73_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019dff77-fa00-7459-b06f-604e67d0db51_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019dff77-fa00-7abb-a3d3-dc6d36247033_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019dff77-fa00-76e9-826e-9a5d05578134_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019dff77-fa00-7415-849f-76a3a000a4bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019dff77-f9ff-7c8f-a173-6ea8bd66b6cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019dff77-fa00-7ec7-833e-f249a8a8e503_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019dff77-f9ff-7e03-98a7-8454b0479053_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019dff77-fa00-76ff-9111-af2ecde39cdc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019dff77-fa00-7546-a36a-a2ea21a87273_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>exel-20260805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019dff77-f9ff-73e7-920a-460f0f3405e9,g:f654a1f8-8503-4e93-9618-208823627eeb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20260805.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019dff77-f9ff-7ffc-bd6e-489c826201a7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_AmendmentFlag_019dff77-f9ff-7ffc-bd6e-489c826201a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019dff77-f9ff-7647-8a7d-ecfc9150dfb8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_DocumentPeriodEndDate_019dff77-f9ff-7647-8a7d-ecfc9150dfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019dff77-f9ff-7d38-acd3-7c4a5911cf54" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityRegistrantName_019dff77-f9ff-7d38-acd3-7c4a5911cf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019dff77-f9ff-7aba-941b-36e327f6f3e9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityCentralIndexKey_019dff77-f9ff-7aba-941b-36e327f6f3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019dff77-f9ff-7f24-a98e-617bda840638" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityEmergingGrowthCompany_019dff77-f9ff-7f24-a98e-617bda840638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019dff77-f9ff-7e4a-ab19-1e0eed1ad687" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_Security12bTitle_019dff77-f9ff-7e4a-ab19-1e0eed1ad687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019dff77-f9ff-71c8-bed2-515b3bea4382" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_TradingSymbol_019dff77-f9ff-71c8-bed2-515b3bea4382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019dff77-f9ff-72fd-96fb-2e271afa3b79" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_SecurityExchangeName_019dff77-f9ff-72fd-96fb-2e271afa3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019dff77-f9ff-754d-b99d-02105591663d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityFileNumber_019dff77-f9ff-754d-b99d-02105591663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019dff77-f9ff-7c9a-bd78-6853ce47468c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019dff77-f9ff-7c9a-bd78-6853ce47468c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019dff77-f9ff-757b-9a53-40ef534e3feb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityTaxIdentificationNumber_019dff77-f9ff-757b-9a53-40ef534e3feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019dff77-f9ff-7e1f-bbd8-6c572f3c2b3b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityAddressAddressLine1_019dff77-f9ff-7e1f-bbd8-6c572f3c2b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019dff77-f9ff-7cab-81d9-fc283f47c83e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityAddressCityOrTown_019dff77-f9ff-7cab-81d9-fc283f47c83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019dff77-f9ff-7182-8872-bbfa8ad6b082" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityAddressStateOrProvince_019dff77-f9ff-7182-8872-bbfa8ad6b082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019dff77-f9ff-7371-832f-90e562e93b43" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_EntityAddressPostalZipCode_019dff77-f9ff-7371-832f-90e562e93b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019dff77-f9ff-7a3c-a36d-4e1851be2a90" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_CityAreaCode_019dff77-f9ff-7a3c-a36d-4e1851be2a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019dff77-f9ff-7a40-89f1-989dd3f6e091" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_LocalPhoneNumber_019dff77-f9ff-7a40-89f1-989dd3f6e091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019dff77-f9ff-7ebd-8616-61a7cf27274f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_WrittenCommunications_019dff77-f9ff-7ebd-8616-61a7cf27274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019dff77-f9ff-739c-b8de-a92af4aeff24" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_SolicitingMaterial_019dff77-f9ff-739c-b8de-a92af4aeff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019dff77-f9ff-7af7-ae29-89a723670158" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_PreCommencementTenderOffer_019dff77-f9ff-7af7-ae29-89a723670158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019dff77-f9ff-70c3-98ee-0c604d81d6a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019dff77-f9ff-70c3-98ee-0c604d81d6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019dff77-f9ff-7fc0-a8c0-47cea6baad83" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019dff77-f9ff-7274-b2d9-1b3439a8cccb" xlink:to="loc_dei_DocumentType_019dff77-f9ff-7fc0-a8c0-47cea6baad83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>exel20260630exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if8ad1b60b8f54903b18a636d1e8bd3c1_1"></div><div style="min-height:85.5pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="image.jpg" src="image.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Andrew Peters</font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">SVP, Strategy &#38; Investor Relations</font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7248</font></div><div style="text-align:right;text-indent:36pt"><font style="color:#006ba6;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">apeters&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Second</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Quarter 2026</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.82, Non-GAAP Diluted EPS of $0.91</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM ET -</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif.</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exelixis continues to execute across the key pillars of our business, positioning the company to deliver on our strategic objectives for 2026 and beyond,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;For zanzalintinib, our next potential franchise molecule, the R&#38;D organization is executing on our priority goals for pivotal data readouts, clinical trial enrollment and new study initiations, while also laying the foundation for the next wave of development opportunities. Additionally, in the second quarter, we saw the continued growth of the cabozantinib franchise while advancing preparations for the potential launch of zanzalintinib in metastatic colorectal cancer, pending approval from regulatory authorities later this year. We are executing on all these initiatives while maintaining disciplined expense management and capital allocation, with a focus on simultaneously investing in R&#38;D and returning capital to shareholders, as well as pursuing opportunistic business development when appropriate.&#8221;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Second Quarter 2026</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Results</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2026 were $628.7&#160;million, as compared to $568.3&#160;million for the comparable period in 2025. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter ended June&#160;30, 2026 included net product revenues of $573.0 million, as compared to $520.0&#160;million for the comparable period in 2025. The increase in net product revenues was primarily due to an increase in sales volume.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 2 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $55.7&#160;million for the quarter ended June&#160;30, 2026, as compared to $48.2&#160;million for the comparable period in 2025. The increase in collaboration revenues was primarily related to higher royalty revenues for the sales of cabozantinib outside the U.S. generated by Exelixis&#8217; collaboration partner Ipsen Pharma SAS (Ipsen), partially offset by lower development cost reimbursements earned. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2026 were $212.0&#160;million, as compared to $200.4&#160;million for the comparable period in 2025. The increase in research and development expenses was primarily related to increases in clinical trial costs, manufacturing costs to support our development candidates, and license and other collaboration costs, partially offset by a decrease in personnel expenses.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2026 were $147.6 million, as compared to $134.9 million for the comparable period in 2025. The increase in selling, general and administrative expenses was primarily related to increases in marketing activities and personnel expenses.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2026 was $50.6 million, as compared to $45.6&#160;million for the comparable period in 2025.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2026 was $212.1&#160;million, or $0.85 per share, basic and $0.82 per share, diluted, as compared to GAAP net income of $184.8&#160;million, or $0.68 per share, basic and $0.65 per share, diluted, for the comparable period in 2025. GAAP net income per share for the quarter ended June&#160;30, 2026 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended June&#160;30, 2026, as compared to the comparable period in 2025, as a result of the stock repurchase programs.</font></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2026 was $237.1&#160;million, or $0.95 per share, basic and $0.91 per share, diluted, as compared to non-GAAP net income of $212.6&#160;million, or $0.78&#160;per share, basic and $0.75 per share, diluted, for the comparable period in 2025. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation, adjusted for the related income tax effect for all periods presented.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 3 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2026 Financial Guidance </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Exelixis is providing the following updated financial guidance for fiscal year 2026. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of zanzalintinib for the treatment of patients with previously treated metastatic colorectal cancer (CRC). The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' New Drug Application (NDA) for this proposed indication, when used in combination with atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:112%">). </font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Guidance </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(provided on August 5, 2026)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Previous Guidance </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(provided on January 11, 2026)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.500 billion - $2.550 billion</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.525 billion - $2.625 billion</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.300 billion - $2.350 billion</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.325 billion - $2.425 billion</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold, % of net product revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5% - 4.5%</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5% - 4.5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses </font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$825 million - $875 million</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$875 million - $925 million</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses </font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$575 million - $625 million</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$575 million - $625 million</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21% - 23%</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21% - 23%</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)  </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2026 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 3.0% for CABOMETYX</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and COMETRIQ effective January 1, 2026.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)  </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $50.0 million of non-cash stock-based compensation.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)  </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $75.0 million of non-cash stock-based compensation.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Cabozantinib Franchise Highlights </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net product revenues generated by the cabozantinib franchise in the U.S. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $573.0 million during the second quarter of 2026, with net product revenues of $570.6 million from CABOMETYX</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (cabozantinib) and $2.4 million from COMETRIQ</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners, Ipsen and Takeda Pharmaceutical Company Limited, during the quarter ended June&#160;30, 2026, Exelixis earned $53.2 million in royalty revenues. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Zanzalintinib GI Highlights</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab for Previously Treated Metastatic CRC and Update on Results from the Non-Liver Metastases (NLM) Subgroup from STELLAR-303. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In June 2026, Exelixis </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">announced results</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> from the final analysis of the dual primary endpoint of overall survival (OS) in the NLM subgroup in the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in previously treated non-microsatellite instability (non-MSI)-high metastatic CRC. The results showed a non-statistically significant trend in OS favoring the combination in the NLM subgroup. As previously announced in June 2025, STELLAR-303 met its other dual primary endpoint, OS in the intention-to-treat population, which included all randomized patients regardless of the presence of active liver metastases. In February 2026, the U.S. FDA accepted the company&#8217;s NDA for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 3 STELLAR-316 Pivotal Trial Nearing Initiation, in Collaboration with Merck and Natera. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis remains on track to initiate the planned phase 3 STELLAR-316 pivotal trial of zanzalintinib in mid-2026. This Exelixis-sponsored trial will evaluate zanzalintinib, with and without KEYTRUDA QLEX</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (pembrolizumab and berahyaluronidase alfa-pmph) &#91;KEYTRUDA QLEX is marketed outside the U.S. as KEYTRUDA SC</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;, in patients with resected stage II&#47;III CRC who, following definitive therapy, have tested positive for molecular residual </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 4 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disease (MRD+) and have no radiographic evidence of disease. Natera, a global leader in cell-free DNA and precision medicine, will provide its Signatera&#8482; assay to identify MRD+ patients for trial enrollment. In May 2026, Exelixis </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">announced a clinical development collaboration</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in which Merck, known as MSD outside of the United States and Canada, will supply KEYTRUDA QLEX injection for subcutaneous administration in combination with zanzalintinib for the trial. The primary endpoint of STELLAR-316 will be disease-free survival, with secondary endpoints including circulating tumor DNA clearance. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enrollment Progress for Phase 2&#47;3 STELLAR-311 Pivotal Trial. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is continuing to actively enroll patients in the phase 2&#47;3 STELLAR-311 pivotal trial. STELLAR-311 is evaluating zanzalintinib versus everolimus as a first oral therapy in patients with advanced neuroendocrine tumors (NET), regardless of site of origin, who have received up to one prior line of therapy. The primary endpoint of the trial is progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Zanzalintinib GU Highlights</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In May 2026, Exelixis announced that the company expects topline results from the STELLAR-304 trial in the second half of 2026, depending on event rates. STELLAR-304 is a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced non-clear cell renal cell carcinoma (nccRCC). The primary endpoints of the trial are PFS as assessed by blinded independent radiology committee and objective response rate (ORR) per RECIST 1.1, with OS as the secondary endpoint.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of Phase 3 LITESPARK-034 Pivotal Trial as Part of Clinical Development Collaboration with Merck. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April 2026, Exelixis&#8217; collaborator Merck initiated LITESPARK-034, a global phase 3 pivotal trial evaluating zanzalintinib in combination with WELIREG</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (belzutifan) versus WELIREG and placebo in second-line or later advanced renal cell carcinoma (RCC) patients who have progressed on or after both programmed death-1&#47;ligand 1 (PD-1&#47;L1) and vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies in sequence or in combination. LITESPARK-034 is the second of two Merck-sponsored phase 3 pivotal trials of zanzalintinib and WELIREG in RCC under the </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">companies&#8217; clinical development collaboration.</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Merck initiated the first trial, LITESPARK-033, in December 2025. LITESPARK-033 is evaluating the combination of zanzalintinib and WELIREG versus cabozantinib in first-line advanced RCC following an immunotherapy administered in the adjuvant setting.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Zanzalintinib Development Program Expansion Opportunities</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of Phase 2 STELLAR-201 Trial in Recurrent Meningioma. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In May 2026, Exelixis announced the initiation of STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I&#47;II&#47;III meningioma with relapse or progression following radiation and&#47;or surgery or those who are not candidates for these therapies. The primary endpoint of the trial is ORR, with secondary endpoints including PFS, duration of response (DOR) and OS. Enrollment is currently ongoing. Pending favorable results, the trial represents an opportunity for zanzalintinib to become the first and only systemic therapy for this form of meningioma, the most common primary intracranial neoplasm for which there are currently no approved systemic therapies.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expansion of Zanzalintinib Clinical Development Program in Squamous Non-small Cell Lung Cancer (NSCLC), Metastatic Bladder Cancer and Metastatic Castration-Resistant Prostate Cancer (mCRPC). </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has additional planned and ongoing zanzalintinib studies across multiple tumor types. These include STELLAR-202, a planned phase 2 trial evaluating zanzalintinib in combination with pembrolizumab in the maintenance setting in squamous NSCLC, as well as expansion cohorts in the ongoing phase 1b&#47;2 STELLAR-002 study. The STELLAR-002 expansion cohorts are evaluating zanzalintinib monotherapy in patients with metastatic bladder cancer who have progressed following treatment with enfortumab vedotin and pembrolizumab, as well as zanzalintinib in combination with docetaxel in mCRPC patients with measurable </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 5 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disease. Both the bladder cancer and mCRPC expansion cohorts in the STELLAR-002 study have been initiated and enrollment is ongoing. Exelixis expects to initiate STELLAR-202 in the second half of 2026.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zanzalintinib and Cabozantinib Data Presentations at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026).</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Zanzalintinib and cabozantinib were the subject of numerous presentations at ASCO 2026, which was held from May 29 through June 2 in Chicago. Notable posters included an analysis of the contribution of atezolizumab to the efficacy of the combination with zanzalintinib in the phase 3 STELLAR-303 trial and results from a subgroup analysis of the phase 3 CABINET pivotal trial evaluating CABOMETYX in patients with previously treated advanced NET. The STELLAR-303 data support the contribution of atezolizumab to the previously observed survival benefits of zanzalintinib in combination with atezolizumab for patients with metastatic CRC. The presentation demonstrated the importance of generating data around the potential impact of anti-drug antibodies on systemic exposures or neutralization of immune checkpoint inhibitor activity, which Exelixis plans to continue to interrogate across all zanzalintinib development opportunities. The results from the CABINET subgroup analysis showed CABOMETYX provided significant improvements in PFS versus placebo in patients with NET regardless of functional status, highlighting the ability of CABOMETYX to delay disease progression for these patients.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Repurchase Program (SRP) Update. </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the second quarter of 2026, Exelixis repurchased $311.6 million of the company&#8217;s stock, at an average price of $47.85 per share, and completed the SRP authorized in October 2025, fulfilling its commitment to purchase a total of $750 million of the company&#8217;s stock under the October 2025 SRP before December 31, 2026. In May 2026, Exelixis&#8217; Board of Directors authorized the repurchase of up to an additional $750 million of the company&#8217;s outstanding common stock before December 31, 2027 (May 2026 SRP). Exelixis began executing stock repurchases under the May 2026 SRP in the second quarter of 2026. Since Exelixis&#8217; Board of Directors authorized the first SRP in March 2023, Exelixis has repurchased a total of $2.9 billion of the company&#8217;s common stock, retiring 93.3 million shares, at an average price of $31.12 per share, as of the end of the second quarter of 2026. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock repurchases under the May 2026 SRP may be made from time to time through a variety of methods, which may include open market purchases, in block trades, Rule 10b5-1 trading plans, accelerated share repurchase transactions, exchange transactions or any combination of such methods. The timing and amount of any stock repurchases under the program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of the company&#8217;s common stock and general market conditions. The program does not obligate Exelixis to acquire any amount of its common stock, and may be modified, suspended or discontinued at any time without prior notice.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended July&#160;3, 2026 and July&#160;4, 2025, are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June&#160;30, 2026 and June&#160;30, 2025, respectively.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the second quarter of 2026 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Wednesday, August&#160;5, 2026.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please dial (800) 715-9871 (domestic) or (646) 307-1963 (international). The Exelixis conference call ID number is 5587241. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 6 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will be archived on </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ExelixisInc</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on LinkedIn.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements </font></div><div style="margin-top:9pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; plans and ability to execute and deliver on its strategic objectives for 2026 and beyond&#59; Exelixis&#8217; belief in zanzalintinib as its next potential franchise molecule&#59; Exelixis&#8217; focus on investing in R&#38;D, returning capital to shareholders, and pursuing opportunistic business development&#59; Exelixis&#8217; goals and clinical development plans for zanzalintinib, including the anticipated timing for pivotal data milestones for STELLAR-304 and plans to initiate additional zanzalintinib trials, including STELLAR-202 and STELLAR-316&#59; Exelixis&#8217; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">belief that STELLAR-201 represents an opportunity for zanzalintinib to become the first and only systemic therapy for recurrent Grade I&#47;II&#47;III meningioma&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> complexities and the unpredictability of the regulatory review and approval process with respect to Exelixis&#8217; NDA for zanzalintinib for the treatment of patients with previously treated metastatic CRC, when used in combination with atezolizumab, including the risk that the FDA may not approve zanzalintinib as a treatment for metastatic CRC in a timely fashion, if at all&#59; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis&#8217; updated FY 2026 financial guidance&#59; the timing, amount, and completion of any stock repurchase programs&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future&#59; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and other statements that are not historical facts</font><font style="background-color:#ffffff;color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 7 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">trials or successfully commercialize partnered compounds in the territories where they are approved&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, zanzalintinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions, including as a result of changing trade policies and tariffs and the related uncertainty thereof&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis, Inc.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">WELIREG</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">, KEYTRUDA QLEX</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8482; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">and KEYTRUDA SC</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8482; </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">are registered trademarks of Merck Sharp &#38; Dohme LLC, </font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">a subsidiary of Merck &#38; Co., Inc., Rahway, N.J., USA.</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:115%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><div id="if8ad1b60b8f54903b18a636d1e8bd3c1_4"></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 8 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net product revenues</font></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">573,025&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">520,014&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,128,002&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,033,297&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">55,665&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48,247&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">111,500&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90,411&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 28pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">628,690&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">568,261&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,239,502&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,123,708&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cost of goods sold</font></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,657&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,470&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,610&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,642&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">211,987&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">200,356&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">411,903&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">412,589&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">147,632&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">134,859&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">287,234&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">272,042&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 28pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">380,276&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">354,685&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">739,747&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">723,273&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Income from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">248,414&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">213,576&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">499,755&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,435&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,210&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,789&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,337&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,865&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expenses), net</font></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">54&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">273&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(195)</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Income before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">262,678&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">230,415&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">530,365&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">436,105&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,628&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,567&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">107,848&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91,641&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">212,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">184,848&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">422,517&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">344,464&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic</font></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.85&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.68&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.66&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.25&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Diluted</font></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.82&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.65&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.60&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.20&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">250,808&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">272,583&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">254,568&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">275,693&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">259,675&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">284,393&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">263,499&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">286,285&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;- more - </font></td></tr></table></div></div></div><div id="if8ad1b60b8f54903b18a636d1e8bd3c1_7"></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.903%"><tr><td style="width:1.0%"></td><td style="width:55.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Second Quarter 2026 Financial Results</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 9 of 9</font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August&#160;5, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">212,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">184,848&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">422,517&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">344,464&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation - research and development</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,344&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,143&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,662&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23,665&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation - selling, general and administrative</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,219&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,928&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,951&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,336&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,512)</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,355)</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(14,269)</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(14,348)</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">237,101&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">212,564&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">469,861&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">392,117&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic</font></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.85&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.68&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.66&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.25&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.82&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.60&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.20&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic</font></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.95&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.78&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.85&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.42&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Diluted </font></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.91&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.75&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.78&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.37&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">250,808&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">272,583&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">254,568&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">275,693&#160;</font></td><td style="background-color:#ffffff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">259,675&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">284,393&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">263,499&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:120%">286,285&#160;</font></td><td style="background-color:#cceeff;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash stock-based compensation used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20260805_g1.jpg
<TEXT>
begin 644 exel-20260805_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /54ED?6GK-_1>D/S<>MMEV]E;!9.P%[MN]^W:YVUOYN
MY<K3]=/KGD5BW'Z:R^IT[;*L7(>PP=KMKZ[7-]KAM24^@I+EOJWUSZU=1ZD:
M>I]/&+AMJ<YUIHNI.^6BIC'9%CFOW?I/HL5/-^N/6^B];^Q=9HH?ASN%]#+&
MN=2XPW)K#[;MSJ?^U&/]/_1_X'U4I[5)4>I=9P.G=,=U.ZP/Q]H=4:R'&PN_
MF64?FV.N_,_])K!^J?UA^L77<JRR^G&IZ=1(L>QEA>ZPB68]5C[=GZ)IWWV^
ME_UO]+^A2GK$EPO4_KOUZOK63T[IV)3:*+#576:[+;7[!-C]M%C/Y3MK:_H(
M9^MWUZ G]D?^R>5_Z42I5O?)+$ZEUCJ/3?JM^U,BA@Z@VJDVT:BMMMKJZGM^
MD]VRJRWZ'J?]=_/4OJIUC+ZSTD9N8VMMIMLKBH.:V&.VMTL?:[_I)*=E)5.K
M9QZ=TO+SPSU#BTOM%<QN+&EP;N_-6-]4NO\ 5.N8.99D-HKOHL].DUM>&26-
ML!M:^U[G>]WYKV)=%#>GH;;:Z:GVV';76TO>[P#1N<5C8'UIHS,QN,ZAU+;3
MMIL<X&3RUMC!_-[OZUBKX'7[LK+?TSJU-=8NW4G9(A_T74V;GO\ YW_!O9_Z
M,1\/ZLXG3\G[;;D.?7CR]@>&M#8!]]MGY_IM_P"+5,YLN64)8"/;$JR\6DH_
MWN+_ +EO#!BQ1R1Y@'W#&\/#ZHR_N\/];]]ULW,IPL9V1=.UL -:)<YQ]K*J
MV_G66.]K%+&^T&AAR0T7$2]K>&DZ^F#^=Z?T-_\ A%B8%K^N=4.:\$=/P#&+
M61]*TC^>?_+97[O^"WU_\*J;OK;U!WUQ;T.NJEN&+?1>]P<;3%)R'/:X/;6S
MW^S^;L4^*?N7,?)\L/ZW[T_^\:^;&,0&,_SGS9/ZE_+C_P"_>L27/_6KZUU]
M!KKKKK%^9>'.8QSMK&,;H;KG?2V[C[&?X5<Z_P"M_P!=Z:_M=W3VMQHW%SL6
MYK W]XO]4NK;_+L4M,+Z$DN<Z;]:,CJO0W]0IQ3C/8_TB]WOJ)C^=H?^B]2O
M=^A]2STJZ;?YW]%3:M?I65?E88MO W26[@(#H_.'TOHN_1[F?HK-GJT_H=B2
MG__0Z[_&)_XG3_X8I_ZI<UT3Z^?L7IE/3?L3;_1+SZAOV3ZCWW_S?HV;=OJ;
M?IKI?\8A ^KIG_N13_U2Q/JY]>.F](Z/1T^_'OMMI-A<^L5EIWV67-V^I=6_
MZ-G[B/1'5Z/ZJ_6A_P!81E..)]FKQBQK;!8;&O<_>7L#O2I]U36U[O\ C4?Z
MT]$Q>L=+>VU[*+L<&W'RGZ"MP'N]1W_<>QOMO_[<_G*ZU6Z)]=>G]:Z@,#&Q
M\BNPUNMW6"O:&L+&F?3ML=_A?W5@_7;ZP6]1RQ]7.ECU@;!7D!AUMNGVX33]
M'TZG>_+=_P!;L_1TY*2GFL'[5U6SI_1GY0IQO5+<?U#[*C;[GEFGZ2Q_\WB,
M?_A+?19Z3+EZYT_ QNG856%B,V44-VL'?Q<]Q_.LL?[['_GO7#]7^H#\?H-5
MN+.1U*@%^8UDD7-=[GLH9^_C?]IMOOM9_P /8M;ZC_6EO5L88&58'Y^.R183
M/K5#VMO_ .-9]#(_[>_POZ-*#RF3U/\ 9'URS.I>F+OL^3=^C+M@.]II_G-M
MFWZ?[BV6?XT++'MKJZ6++7N#65LR)<YSCM:QC6XWN<Y9)ZG1TKZ\974+VNLK
MHR;]S*]I>=['5-V^HZMOTG_OKHO_ !S.C_\ <3*^ZG_WH24Z/U[_ /$MF?UJ
M/_/]*!_B\_\ $X/^/N_ZI-]:\VO/^HUF=6UU=>4S%N8U\!P:^['>W?M+F_G?
MO+!^K'USZ=T7I0P<BB^VP666;JO3+8>=S?YRVMW_ $4E=7L/K5_XFNJ?^%;?
M^I*P?\6?]"ZA_P"&&_\ GNM'ROK)B=?^JW6[,6JVEN-18Q_JA@DNK]3V^E9;
M]%I0/\6>N#U C4?:6B>T^E6DKJVOK=@U,LJSF.#;+3Z=C08)+1NKM9_*KV[7
M?]:5'J?7,O.PJ,:P>F"T.O>=&VD$M99I_P!I_9O?_P )_P 5^DO/J?\ 6/K#
MB"?V;B?H]X.CN[Q7_+O=^<W_ +3^G_I%H?6'I#<K!;9C5@78@_1L8.:Q].AK
M6_R1^B65DQ9,GOY,1X<<M.'_ #W#\\A_+UNSCRX\7W;%F]62.O$?\AQ_S<3_
M ,W_ &;H=.PZL'"JQJCN:P:O_><?<^S^VY< W_\ *7_Z%G_VV74?53JK;Z/L
M%CILH;-!_>J_=_ZS]#_B_37+M(/^,R!J?M9T[Z8JO\O.$\490TC5</[M?HN9
MS6.>/-..365WQ?O\7Z3I?7_ZO]0S,BGJF%4[);75Z-]58FQH#C95=77]*WW6
M/]3T_P!)_-_\)Z>?A?XR.JT.%.?CU9+F:.@NHNT_.?6X6,W_ -BA;WUH^M^7
MT'.HH;@^KCV-#G9%CRQKB21Z%#VML;ZK-NYWJ_\ J19O5_KO]7NH].LJNZ?;
M?:YA%;+V5AK7$?3]=MCW5[/])3^E4S"]1T/KN!UO$.1AES36[9;2\ /K=$[7
MM:7-]S?H/8[TUI+B/\66'D,HS<]X(HR/2KI>=!9Z7J^I:S_@]UVS?_QB[=!+
M_]'U#)Q,7+J]'*IKR*I#O3M:'MD?1=M>'-57]@="_P#*W$_[8K_\@KZ22FMB
M].Z?AN<[#Q:<9SP \U5M82!QN]-K=RAC](Z3BVB[&PL>BUL[;*ZF,<)^E#V-
M#O<KB22E*HSI/2Z\D9=>'0S)!+A>VI@LW.!#W>J&[]S]SMRMI)*:5G1.C6V.
MMMP,:RRP[GO=2PN<3^<YSF;G.4?V!T+_ ,K<3_MBO_R"OI)*17XV-DTFC(J9
M=2Z-U5C0YAVG<V6/EOM<U5?V!T+_ ,K<3_MBO_R"OI)*:[.GX%>,[$KQJF8K
MY#Z&L:*W;OI[J@-CMRI9]3:,=G2>E5LQK<O< *FAK:J_^U.3LK#6_G;&?\-:
MQ:J&WT?6?MV^MM;OXW;9?Z6[\[9N]79_UQ,R"X'6A7J[\/Z5,F$UDB:$C?I!
M^7C_ $.+B_188.%CX.,S%QV[:ZQWY)_.>_\ E.1TDD8</"."N&O36W"MGQ<<
MN.^.SQ<7S<7Z5H&8.$RWUV8]3;I)]0,:'2?I'?&[W2F9@8->2[+KQJF95GT[
MVL:+'3'TK0-[OHM5A)*/#1X:WUX>ZI\=CCO;3B[,+:JKJW57,;96\0YCP'-(
M_E-<J#?JU]76O]1O3,0.YGT6?^16DDG+5@   ! &@ 3I))*?_]D .$))300A
M      !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
M     JUOG51>@&54^DS'8    "@/7*+4U EM%KZ\M0  *Q.AO0V N'\T R)]
MKX=K?H;S7S/Z?R[3/6I/SGZ;Q]\;[0!-@_<O2$L>Q.LP !L#RU;8:P"VBFEG
M-+@     =*17->E6]Z;0 [N>FK'<       >:;;'&Z +5Z7M*IH       .*
M//CKC@&8 TET--,8(JOO0 2\BU\.6OZ   \^6N,:Y@"Q:M[B\]      !5K?
M.JB] ,JI])F.P    % >N46IJ!+:+7UY:@ #!?$N95==!^B?J!S7ZORVN^AO
M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
MN''P#<99VIFT^2=%>\:SD,_/U6C7] KT*O,=6DC;W+^))C!A6# ](0(,5MSL
MH&60""(@\IJP;#SKZ?\ SC]3?G3_ .<?J;\Z0^!#4S?G0ON,PANH]AR#W=X0
MSHTF<I1U,"#:/MZ^%9^[L5=;_81>#>#0)O?@S,:S+/'65U&([5 TIE<&]2&_
M"D6J&=7XT/*F"8XZ*;1XSS1QGBI!]B4O-06:V/2;,V7 : 1 2S&  M)-@IMP
M,^9SSU1U!D.EB<@.!]XFF"((G/ #-C4*3-XF\YS'5@!D!4/,-7F.'EHZ$/,<
M/('<)IVY8BF:7KW;1V8X:)GRE\>4(YN@M7,CG+QB_1BI(U4VF)UDG2&_;ROB
ML-@'H*>D>TUV"UVFK@7^WRS4FU,S;HKW16<SE]/APP\UP\ZI/E&#H8@_:XV'
M*B;S*L<5CJL.<O$?5 Z$:?&E"$F=$C!6Z2^U<CEY(;[O*^$AV0?]1A^Q;\35
MC2O@F;RUJB"CK.>:/:<@:-,F&+,22<2:SYC'U@^7FF$J<0/=?HMJ/-;*!NI#
M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
M=1W>M5MTZ]HUZ3UG#RX5W#.[D%HJ6%FN%J9@#@&I:A]] 3_I2KAT:3',F4ZB
M\6%#[SG"P1RU]O=>8R;B=; >U*BCH8[=.K:JB279U+. ^/M3K_NTAI,CY.K:
MBB=PM1F:X1R45IIP=K254J@/@->[$'8\PTGIJ6<7[.E]6-\VYNDCW&G9,2E/
M3H2>JIXB3NKCB3BS$DZO0EIZB))X)T:.:"10R.C#!E93B""#@0=)N('_ &U9
M_J>$>9I"Q>Q;\JVW!SO/'!)#C)#&Q_RG26+UJJ-6B6V.[Y/KH$'5B^.+<7(V
M;YQAC)/_ *7IC2CSC_W3<5*K/DU&V]391MLTHI@C'%H6J"L(BC)U,M-%&6&U
M]*"RV2WT]IM%K@2FMMMI(UB@@AC&ZD<:* %  U =CXN??2^^/S<CC7]8V/Q>
MI_ :[CQD.WXP28/Q/LM,FL:MT7>-%VX:EJ,.;"3F<Z @X@[".0V5LUUSKPMS
MA4C^8.Y+)9[C)@B5ZCFBDU+.!LU2>I;&.:&198I5#Q2H0RLK#$,I&H@C8=+E
M?;W70VRSVBFEK+G<:A@D4$$*EY)'8[ J@G1[M"T]'D3+S2TV1+)+BI$3'"2O
MG38)JD '#U"8)MWL?1:21@B("SL=@ VZ0\7L]6\Q9YS)2%<LVBH3"2SVR<=\
MZGO:BI7 OSHF";2XY?%;X[0?9E)R.)GW8H_'#V?@I]8WSQ>FY'!S[YV?QE.R
M<1OU%F^SH>1DSZJOGB9Y5URO7D1/4J);96X8M35D6)AF7VK:CTJ2.?2X66[4
MYI+I::AZ6X4Q]1+&<#@><'45/."#R(*FEG>EJZ61)J2JC.Z\4L9#(ZGF*L 1
MI1W:1DCOMO(HLRT:X#JZI%&+JO,DHP=?3PYN377B[UD=OMEMA>HKJR8X)'&@
MQ)/_ - -9V#1KE)UM+EZVEXLLVA]751'4T\J[.MEP!;UHP7F./H$[K.=05%&
M+,3J  YR3J TI*:NA"9COA6X9B;U2RNOO<&/1"F"^GO'GY5R^*S>X.A]N_NC
MR.+_ -?V[Q$<CBE>8M4MORK=I8"/]04D@39[(C2"(;(HU0?B '(:\01**_,F
M9;K/<JC ;SFEE%'$I.W!4A& [9[ :N7+EKEJB=XU+T<#28].\4QT554*J@!5
M P  V #\#XN??2^^/S<CC7]8V/Q>I_ 9J:IACJ*:IC:*HIY5#I(C@JRLK8@@
M@X$'3^<9?IG?A=F^I=LN2C%A:ZML7>V2MKP7#%H"=J8IK*:_1*L RL"&4ZP0
M=H(TM_ ?/EQ)K*6-DX9WJI?7/!&"QM4CMMDB4$PD]\@W-J &JX.9'N/69+R[
M5!<ZW6G;WNZW&G;'X&C#OH*9QW?,\HPUA-?(I.+>=J$/D++-9CEBUSJ"EXN=
M.W^,Z-WU/2N.?4\@PUA&!Y?%;X[0?9E)R.)GW8H_'#V?@I]8WSQ>FY'!S[YV
M?QE.R<1OU%F^SH>1DSZJOGB9Y<7$ZSP8S4,:4N;84&MZ8=S#58=,1.ZWL2#Z
MGDTUVJ'<Y>NBK19FIUUX0%L4J /70,=[I*[PY](JBGE2>"=%D@F0AE=&&*LI
M&H@@X@^B6)  UDG8!HV4\N5!.3;+.?A-4A[FYU<1PW]6V&(CN/7-W6P+R#F*
MXP"3+^3'2=E<8I/<&&]3QZ]HC'OC=O=Z>7<OBLWN#H?;O[H\CB_]?V[Q$<CB
M_3P+OROE&[E5&LG<I9&(&':&B$:P5!!_%R*_A/G^X):,N9AN)K\IYCJ65*6C
MKJ@*D]+52-@(TF959'8[H?>#8;P.B21L'1P&1U.((.L$$;0?POBY]]+[X_-R
M.-?UC8_%ZG\"OF1LWT(K[%?J<PU* [LD3@[T4\+[4DB<!T8;"-+GD/,P-0],
M/A-AO83<BN=N=BL55&-@.K=D4'N7!&S#'T8:BGFDIZBG=9:>IA=HY(Y%.*NC
MJ0RL#K!!Q&G]Y],ZR>0EA0ST.3;'U55GN_Q=R8:9R=RDA?# 3U.!"^M7>?F&
M-JR[EZW0VBQV2EBHK5;*==V*""%0J(H[0'/K//V#BM\=H/LRDY'$S[L4?CA[
M/P4^L;YXO3<C@Y]\[/XRG9.(WZBS?9T/(R9]57SQ,\NJH:V%*FCK87@JZ:08
MI)%(I5T8<X()!TK\NOOR6J8&LRW6-KZVB=L%4GG>(]PWXCS\C6,1SC1^'%YJ
M,;G8(C-ER:1NZGMX.!AQ.LM3DX#V!'K3Z-7PURG6%:R>/<S?=8&P,$3C^"C8
M;'D4^^$=ZO<[6U!5 50,%4:@ .8>C1VVW4[5=PN,\=+04B#%I9IF"(@PZ2=+
M1EBE*RSTZ&:[5@&'PBLF[J>7TBVI>A0!R[E\5F]P=#[=_='D<7_K^W>(CD7V
MP3G=@OENJK?,QUX)4Q-$Q_(VE99JU&CK;+4SVZLC;OA+22-!(#_S(>0RLH96
M&#*1B"#M!&E-;LKYH_FF6:8C<RA?4:NH40$DI Q99H <=D<@7V.D%-Q(R#=<
MLU.Z!/=;+(ETHR^.WJFZFH0=H*^B1Y;XG622L8 _RRNG_E]4"?4]16"%R1V@
M=$EB=98I &CD0AE8'801J(_".+GWTOOC\W(S[!?\LW7,39OJK?/2-;&IU$(H
MXI8V$G7R1ZV,@(PQT\VN:?VE!\XT\VN:?VE!\XT\VN:?VE!\XT\VN:?VE!\X
MT\VN:?VE!\XT\VN:?VE!\XT\VN:?VE!\XT\VN:?VE!\XTRED6AR!F.WUN;[G
M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 1,# 2(  A$! Q$!_\0
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M2W1^V&G2M<6%O*^-\D:NV.F2 3BK-5-)_P"059?]<4_]!%6Z19Y+^TO\;'^
M_P .SK]OIZZGJ-Q<)96<$K%8O,8,VYR.=H"G@<GBO&_V4_VKO&?QL^)MUH&O
M6NE0V":=+=J;*%T?<KHH&2QXPQK1_P""C/\ R1W0O^PY%_Z)EKPG_@GG_P E
MVO/^P)/_ .C(JNVA%]3Z^^._Q$\7?#-[&_TN"SN-&N/W3O-&Q:*7L"0>C#./
M<5S7PG_:6O/$WB2#1_$5M:VXNCLM[JWRJA^RL">_8U[=XQ\,67C+P_>Z/?H'
MM[J,H?53V8>X.#7P9XI\.7_@OQ)>:3>[HKRSEP)%XR.JNOUX(K\US_%8_*<7
M#%4YMTI;KHN_W]#].X=P679SA*F#JP2K+:75]ON>Y]0?%3]F^U\=ZQ)K&E7P
MTK4)_P#7I)'NBE;^]P<AL>E:7PD^ =G\-;UM4NKS^U-79?+64)LCA7OM'J?4
MU?\ @7\2E^(7A&+[1(O]KV.(+M.[<<28]&'ZYK'^/WQB'@72SI&F2@Z_>)PP
M.?L\9XWGW/;\^U>FZ>44H?VURI7U^?\ F>-&KG5>?]A\[T?+;R_R.-_:*^,#
MWT[^#?#\C22,_EWTL)Y9B<"!2.^<9_+UKUOX/_#U/AYX)M-/*J+^7]_=R+WD
M(Z#V P/PKP+]F?X>'Q-XHE\17R%[/37S'OY,EP>Y]=H.?J:^MUZ"GD<*N.J2
MS3$K5Z07:/\ P2L^E1R^G#*,*](ZS?\ -+_)=#X5^-'[>WBCPS\0M;T+PKI.
MF)IVE7,EF;C4$>26:2,[7; 8!5W @#T&:^POA5XFN_&GPS\,:_?K&E[J6G07
M<RP@A [H&(4>F37Y+_&;_DKGCG_L-7O_ *.:OU2_9]_Y(9X#_P"P+:_^BEK[
M5GQ$7=LY_P#:"_:5\.? 32X!>(^J:]=J6M-)@8*[J.-[L?N)GOU/8&OC+Q%_
MP4!^*.K7+-IQT?0K?/RQ0VOGMCW9SS^ %>?_ +4?B*\\1_M >-KB]=G>UU!K
M*%6_@AB&U% ]."?^!5]9?LG_  !^$WBOX3:3K%UI>G^*M=NHMVH->/YK6TF2
M#%Y><)C@=,GKWI[$WNSQ3PW_ ,%!_B;I-PIU6WT;7;?/S+);&W<CV9#C/U%?
M6_P%_:L\*?'9O[-MQ)HGB5$,C:3=L&9U'WFB<<.!^!'I6'\0/V$OAEXNMW.D
MV,WA._;[MQICDQ_\"B<E2/IBM[]GW]E7PY\!7O;^VO)]<U^Z7RFU.ZC5#%%U
M\N-1PH)ZG))P/2D[="TGU,+Q1\7/%3^-;*RTR_@TZVO;F2VT^U\@2M<%+DVY
M,FY3DEE=RH9,(O!)KVWP+X@;Q5X4T_5)(1;S3H1+$K;E616*.%/==RG![C%<
MMKWP1TW6-2OKJWU.^TN+4&#WD%L(R&8,'W1LZEH6+C=E"/FY&#S7=Z/I%IH&
MEVNG6$"VUE:QK%#"G1% P!4E%RBBB@!#7Y'?M/\ _)PWQ _["C?^@+7ZXFOR
M._:?_P"3AOB!_P!A1O\ T!:J)$MC2\(_M<?$_P "^&M/T#1=<M;;2M/B$%O$
M]A%(RJ,X!8C)[UK_ /#<GQBZ_P#"26>/^P9#_A7UE^SC\!?AUXH^!G@O5=6\
M&:/J.I76GK)/=3VJM)(VYN6/<UZ2O[,_PJ5@1X T($<_\>:T.P:F#^R-\0O%
M/Q0^#]MX@\5W"W5_/?7"1S+ L*O"I 4@+P1G=SWQ7M=4]-TZVTJSM[.SMXK2
MTMT$<-O"@1(U P  . *LR3"+EN% R6)P!4EG@O[8WPGT#XB?"J_U74KJWTC4
MM B>ZM-3FX"\<PMW*OP,>N"*_+M3E58C!Q^7>OI3]LC]I(_%KQ*_A?0+D_\
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M'PSX=T[0VN,"5K*V5&<#H"1R1[4M!ZG2W'_'K+_N'^5?B9=?\A*X_P"OEO\
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M6Y^-WQF_Y*WXY_[#=[_Z.:OU2_9]_P"2%^ _^P+:_P#HI:_*WXS?\E;\<_\
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MHR<[(4"#/K@5\SDN35<IJ3M5YH2Z6/J,\SZGG4*;E1Y:D=+WW78_'GXP?O\
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IG-W;U"DVBEHK0@3:*-HI:*5@"BBBF 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 05, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20260805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20260805.htm">exel-20260805.htm</File>
    <File>exel-20260805.xsd</File>
    <File>exel-20260805_lab.xml</File>
    <File>exel-20260805_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20260805_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20260805.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20260805",
   "dts": {
    "inline": {
     "local": [
      "exel-20260805.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20260805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20260805_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20260805_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20260805.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20260805.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000939767-26-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-26-000096-xbrl.zip
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M @[F!KP(L0ODJDWLTI%_3*[>D)M?FX>+_YQ3G#K$B\8-XFV[A>)ZQ.?DQ3T
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M. X-'L?@1I(CR1AYRR(F0(E;$8P=Z7CPPG1,C2XFR+?))/,(8X.:7=V&[Q?
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M,)^2CBR4=WY2>Q41?15'YVO2ZS@G)+MZ<8)%<28YRKX?0U@A1V 0*-@&+((
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M[B ?$'-2Y6UU.N]0UE%:9^PGV6U:,%RU_?^+=72&_8XO1\]02P,$%     @
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M7@#* ($Q0+8&0,,HMQHA:J"6I!!BV3$0!D8-"2F<C)R"D@KRUT;00[#=1GH
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M6".4_[.U=<?,\9"PU;HN:2GAB41+9?[2[K%!2V>/D[1REKZ^&R(A/6I="UN
M_OK@NF!.ZH5-*:4"6N;1H>YK(R?'Q#*^J2DN5MB >O:E8T).K@[>?(W+3:]0
M?:!RF=9/.^Z0>R1?(+-*07%MOMR4?_X6D,>"L5Z=7@S*7?AZL#JG/^0!8L_#
M[U9LO0P+&WY]2]8E&_QJ6>82-;J:7RLX,?1?$#=E>KXE=,S ON*/]99FO5J2
M'U.)7>BY]EGM60*7IM"K]@#>F+BC50YXED"'PCQWM8]+)TK"UIV_O3;8>K-(
M?=O0OJJ&XY[[\WN:-<JV7&^YM?L=.+JMOY-I; $M[XW7G.O6S]9>.^KNO#"5
M&C&J3,=RV^TP,&_IB>#QJ>YT]Q="+L1>CSY9S4[%%6VG[/$@6_)I:#QHUY)(
M)%_6P9AQ%;''5V\Z<%*_(*EP>)=XZ/U'S8&)B.GW&VWO"S*O)5OACUWVC"U[
M3^U^J&@J:," ZK;QJ&*;ZZBB[E^?KQTJ)V<D$!.5Y"MVN=OF]0AG#@X5E[!F
M_P=-2W(^6L=,'IV]YRKR136B.*/<:S7H'@Q9?O#XHER,'S[EAIUD0>M[("^]
MX%[=FOGUAT4]FWY-80VVS^Y%#.KVA [4EO5,#_F]#<NJGB_S6O0+ZV62HCK3
M<R&P>F;SAA1"]IK ^<NK1U8"M@#-Z.@%&Z=/R(]#TGLYJ]WO^W]);0O: N*_
MX*_I<!P^<+;"O=/.NR!U+T?%=&S[WKVOGJU:G4E4,"SO=54QJM)?A+%Q"HYS
MSE8/"">=.>=@\/!K4UZ258CRNZ9H3LF% EA0;;3E^6MQ-%QL@PY<$ZF<L<K]
MQ\1>BM[+S_>UEBRSFJ5%UN/T-LWM<^4G>KM[ZKHPAHVT(R$L85^LKNFW6H$K
M57IX.,DX'SB3O-WZMN?@SPV'M)@$H*"A;T1"0ES0'N2 V (P=GY=#L+2'P X
MH*0 BW8 R@,=@,8Y&F+<,(YFNAJ.A%T)D8N?R$4_%27N*> 5F8E=OYJU^#SI
M.;%-B;A"IB*T[VP2P'V#-Q;<V1C[XKU]\6"5L., 3'!X<V<,QH-(H>^%1Z&\
M?#UW8<)=TP-+J-,1><W1 00*#32>P/-3)@I[#.&)LM"VL2#NP#0!!. %8, /
M#X &;  Y0 &0 /]X !R  K @#@5"P ^Q)E@,QM4<A??U-G8^A031U( )2(8!
M_UQ!)G.0' _X MY$%DKO']2[EFEXX+UV]*9V]D5[X-%>1)%@G8)(K6ETW&#;
MT\H$>JCH;WYA_,4OQMYX-,:+H-Q>HO7>>*]=4T%7.&-_5,S<<$8_6[!>FC\K
M7OB?%4-G#]R/RC$WO-^/BK:GA]:/"NCMGZ(UD.YN.X[8V>N W:X);.^= 3,7
M'AX7C*^S.N8CL%MTL5[_@-/P^$<Z#:R+A:477N> F0<>^*5H>+CP_ EOAO/
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M- @3WDIA]D0A< ! _!Z9#X]"GB3\WH;PS3/6PDP3A \# #FUVR^P\R\P'A5
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M9DAA!1!&GC7WZ';<$\L?7BN"QA$N.#3Q91I T\R"!^F+]=MN([X_0PI0 G0
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MMKV1'ZC[(N89D__Q\0.?&^9%VA8^MO<5VSI>)2279,_BIC%H]WC0T>QP8N8
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MO-_F%D(]PC=(%^Y<?X3^A3ESR]DYJVJ[F'@CWM5K]QN2$]YG[;L/?V%U+[-
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MF*UL+&G^&I(RW3+O6](L(.N,&1>M8)9+VZA 2JN;5913$%<< ^/KK.K'E%\
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MMWZWP?T;NM_V%OY]D)]2"8ZGY*'18W].B6'?%I)$Y5CF ATG[=:4(]&"8TT
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M'S1G6ZZMX]>0QVM-:XI+*X81JO@%[?7[M^P?IE80:ZFH&?. 8!4M9MR+ @I
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M+.JX!"CP"S V,"Z$.&&9NX>4NX*JI7 _#/B,*"%KV B->Y#R ,-&Y&J0O/M
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M!]S#>"\<+_U<H5G&JLH3F/SA%EC'++KW2+UJZX7YO$,(>>#3452#4D7"$B\
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M@3D3Y OP#CT8UAE)[>BL_W8B6TD::!OPQ<]5E?C1Q>*5O0S7[4X(_#N(Y;=
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M7S_7<1/)W=]&M4&31U$6>JB-@$&'4Z;'8SCN]G<G38;S#O=0*1!3J0K]A\)
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M"KA]N2-9PX+CK*INP+TP%JR9?^P!(*P3'!F_<$YDOW_ ?A=!-U "[EWN5.)
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M/<<9QP=SQ0- +[*G#'X%6R-G@L$>1D![#%;VF,.G,0(&8!79:D\Q$]&Y'CB
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M-&_,V9%K63?G<5/ 6;D1Y 4']NT&\;"*."#ETO&&-(-@+,-0Z E^_?_JG%-
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M/AIF2N@83R9^FL<@OB^? 3:(7$O[K!"U46"P42SWXQ!37&"- C'9$X#%%F"
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M/U!+ 0(4 Q0    ( #&A!5V]%101 Q   $EI   1              "  0
M  !E>&5L+3(P,C8P.# U+FAT;5!+ 0(4 Q0    ( #&A!5VDKP[G9 (   8'
M   1              "  3(0  !E>&5L+3(P,C8P.# U+GAS9%!+ 0(4 Q0
M   ( #&A!5W5W1!EJJ<  (?8   4              "  <42  !E>&5L+3(P
M,C8P.# U7V<Q+FIP9U!+ 0(4 Q0    ( #&A!5U0;)$A2PD  'U5   5
M          "  :&Z  !E>&5L+3(P,C8P.# U7VQA8BYX;6Q02P$"% ,4
M"  QH05=,>'C+-\%  #J,   %0              @ $?Q   97AE;"TR,#(V
M,#@P-5]P<F4N>&UL4$L! A0#%     @ ,:$%7968J\G^-P  55H" !H
M         ( !,<H  &5X96PR,#(V,#8S,&5X:&EB:70Y.3$N:'1M4$L%!@
0   &  8 C@$  &<" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>exel-20260805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20260805.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
